Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients... ORIGINAL ARTICLE Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial Chandra Prakash Belani, MD,* Yi-Long Wu, MD,† Yuh-Min Chen, PhD, MD,‡ Joo-Hang Kim, PhD, MD,§ Sung-Hyun Yang, PhD, MD, Li Zhang, MD,¶ Patrick Peterson, PhD,# and Mauro Orlando, MD** Results: Of the 663 patients enrolled in the study, 481 patients had Introduction: In a recent global phase 3 trial, patients with ad- nonsquamous NSCLC: East Asian  27% and non-East Asian vanced non-small cell lung cancer (NSCLC), who had not pro- 73%. In the East Asian subgroup, there were more women, never gressed after four cycles of platinum-based induction chemotherapy, smokers, and patients with adenocarcinoma. PFS was similar be- were randomized to maintenance therapy with pemetrexed or pla- tween the subgroups and significantly prolonged in patients treated cebo. The objective of this retrospective, exploratory, post hoc with pemetrexed than placebo (median PFS: East Asian, 4.4 versus subgroup analysis was to compare outcomes of East Asian patients 1.6 months, HR  0.42, p  0.001; non-East Asian, 4.5 versus 2.8 with non-East Asian http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial

Orlando, Mauro
Journal of Thoracic Oncology , Volume 7 (3) – Mar 1, 2012
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/efficacy-and-safety-of-pemetrexed-maintenance-therapy-versus-best-bSYqqYZ5EZ

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31823d4f9d
pmid
22157370
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial Chandra Prakash Belani, MD,* Yi-Long Wu, MD,† Yuh-Min Chen, PhD, MD,‡ Joo-Hang Kim, PhD, MD,§ Sung-Hyun Yang, PhD, MD, Li Zhang, MD,¶ Patrick Peterson, PhD,# and Mauro Orlando, MD** Results: Of the 663 patients enrolled in the study, 481 patients had Introduction: In a recent global phase 3 trial, patients with ad- nonsquamous NSCLC: East Asian  27% and non-East Asian vanced non-small cell lung cancer (NSCLC), who had not pro- 73%. In the East Asian subgroup, there were more women, never gressed after four cycles of platinum-based induction chemotherapy, smokers, and patients with adenocarcinoma. PFS was similar be- were randomized to maintenance therapy with pemetrexed or pla- tween the subgroups and significantly prolonged in patients treated cebo. The objective of this retrospective, exploratory, post hoc with pemetrexed than placebo (median PFS: East Asian, 4.4 versus subgroup analysis was to compare outcomes of East Asian patients 1.6 months, HR  0.42, p  0.001; non-East Asian, 4.5 versus 2.8 with non-East Asian

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Mar 1, 2012

References

  • Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer
    Baldwin
  • The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies
    Scagliotti
  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    Ciuleanu